Eton Pharmaceuticals (ETON) said Tuesday it has out-licensed commercial rights to Increlex in territories outside of the US to Esteve Pharmaceuticals.
Increlex is indicated for the treatment of growth failure in certain pediatric patients.
Financial terms were not disclosed.
Under the terms of the deal, Esteve will license non-US Increlex rights for up to 10 years and will receive an option to acquire the international rights in the future, the company said, adding it will supply the product to Esteve at a fixed transfer price.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.